Patents by Inventor Nils Lonberg

Nils Lonberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OPTIMIZATION OF ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOF
    Publication number: 20150307609
    Abstract: The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.
    Type: Application
    Filed: July 9, 2015
    Publication date: October 29, 2015
    Inventors: Nils LONBERG, Mohan SRINIVASAN
  • TRANSGENIC TRANSCHROMOSOMAL RODENTS FOR MAKING HUMAN ANTIBODIES
    Publication number: 20140380515
    Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.
    Type: Application
    Filed: July 24, 2014
    Publication date: December 25, 2014
    Inventors: KAZUMA TOMIZUKA, ISAO ISHIDA, NILS LONBERG, EDWARD L. HALK
  • Transgenic trasnchromosomal rodents for making human antibodies
    Patent number: 8835712
    Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.
    Type: Grant
    Filed: September 9, 2010
    Date of Patent: September 16, 2014
    Assignees: Medarex, L.L.C., Kyowa Hakko Kirin Co., Ltd.
    Inventors: Kazuma Tomizuka, Isao Ishida, Nils Lonberg, Edward L. Halk
  • HUMAN CTLA-4 ANTIBODIES AND THEIR USES
    Publication number: 20140234331
    Abstract: The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
    Type: Application
    Filed: April 28, 2014
    Publication date: August 21, 2014
    Applicant: Medarex, L.L.C.
    Inventors: Alan J. Korman, Edward L. Halk, Nils Lonberg, Yashwant M. Deo, Tibor P. Keler
  • Human CTLA-4 antibodies and their uses
    Patent number: 8784815
    Abstract: The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
    Type: Grant
    Filed: November 1, 2012
    Date of Patent: July 22, 2014
    Assignee: Medarex, L.L.C.
    Inventors: Alan J. Korman, Edward L. Halk, Nils Lonberg, Yashwant M. Deo, Tibor P. Keler
  • OPTIMIZATION OF ANTIBODIES THAT BIND LYMPHOCYTE ACTIVATION GENE-3 (LAG-3), AND USES THEREOF
    Publication number: 20140093511
    Abstract: The present invention provides isolated monoclonal antibodies that specifically bind LAG-3, and have optimized functional properties compared to previously described anti-LAG-3 antibodies, such as antibody 25F7 (US 2011/0150892 A1). These properties include reduced deamidation sites, while still retaining high affinity binding to human LAG-3, and physical (i.e., thermal and chemical) stability. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided, as well as immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies. The present invention also provides methods for detecting LAG-3, as well as methods for treating stimulating immune responses using an anti-LAG-3 antibody of the invention. Combination therapy, in which the antibodies are co-administered with at least one additional immunostimulatory antibody, is also provided.
    Type: Application
    Filed: December 2, 2013
    Publication date: April 3, 2014
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Nils LONBERG, Mohan SRINIVASAN
  • Chemical linkers with single amino acids and conjugates thereof
    Patent number: 8664407
    Abstract: The present disclosure provides drug-ligand conjugates that are potent cytotoxins and include a linker between the drug and ligand where the linker has a single amino acid. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.
    Type: Grant
    Filed: February 20, 2008
    Date of Patent: March 4, 2014
    Assignee: Medarex, LLC
    Inventors: Liang Chen, Sanjeev Gangwar, Vincent Guerlavais, Nils Lonberg, Qian Zhang
  • HETEROLOGOUS ANTIBODIES WHICH BIND HUMAN CD4
    Publication number: 20130039850
    Abstract: The invention relates to transgenic non-human animals capable of producing high affinity human sequence antibodies. The invention is also directed to human sequence antibodies specific for human antigens, such as, human CD4. The invention is also directed to methods for producing human sequence antibodies.
    Type: Application
    Filed: July 9, 2012
    Publication date: February 14, 2013
    Applicant: GENPHARM INTERNATIONAL, INC.
    Inventors: Nils LONBERG, Robert M. KAY, Dianne M. FISHWILD
  • Human CTLA-4 antibodies and their uses
    Patent number: 8318916
    Abstract: The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
    Type: Grant
    Filed: August 4, 2011
    Date of Patent: November 27, 2012
    Assignee: Medarex, Inc.
    Inventors: Alan J. Korman, Edward L. Halk, Nils Lonberg, Yashwant M. Deo, Tibor P. Keler
  • Transgenic non-human animals for producing chimeric antibodies
    Patent number: 8293480
    Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: October 23, 2012
    Assignee: Genpharm International
    Inventors: Nils Lonberg, Robert M. Kay
  • Heterologous antibodies which bind human CD4
    Patent number: 8231877
    Abstract: The invention relates to transgenic non-human animals capable of producing high affinity human sequence antibodies. The invention is also directed to human sequence antibodies specific for human antigens , such as, human CD4. The invention also is directed to methods for producing human sequence antibodies.
    Type: Grant
    Filed: April 29, 2010
    Date of Patent: July 31, 2012
    Assignee: GenPharm International, Inc.
    Inventors: Nils Lonberg, Robert M. Kay, Dianne M. Fishwild
  • Transgenic non-human animals for producing chimeric antibodies
    Patent number: 8158419
    Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.
    Type: Grant
    Filed: September 26, 2008
    Date of Patent: April 17, 2012
    Assignee: Medarex, Inc.
    Inventors: Nils Lonberg, Robert M. Kay
  • HCO32 AND HCO27 AND RELATED EXAMPLES
    Publication number: 20120047585
    Abstract: The instant invention relates to transgenic non-human animals capable of producing heterologous antibodies, transgenes used to produce such transgenic animals, transgenes capable of functionally rearranging a heterologous D gene in V-D-J recombination, immortalized B-cells capable of producing heterologous antibodies, methods and transgenes for producing heterologous antibodies of multiple isotypes, methods and transgenes for producing heterologous antibodies wherein a variable region sequence comprises somatic mutation as compared to germline rearranged variable region sequences, transgenic nonhuman animals which produce antibodies having a human primary sequence and which bind to human antigens, hybridomas made from B cells of such transgenic animals, and monoclonal antibodies expressed by such hybridomas.
    Type: Application
    Filed: August 8, 2008
    Publication date: February 23, 2012
    Applicant: Medarex, Inc.
    Inventors: Daniel K. Rohrer, Nancy Amelia Black, Nils Lonberg
  • Human CTLA-4 Antibodies And Their Uses
    Publication number: 20110296546
    Abstract: The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
    Type: Application
    Filed: August 4, 2011
    Publication date: December 1, 2011
    Inventors: Alan J. Korman, Edward L. Halk, Nils Lonberg, Yashwant M. Deo, Tibor P. Keler
  • Human CTLA-4 antibodies and their uses
    Patent number: 8017114
    Abstract: The present invention provides novel human sequence antibodies against human CTLA-4 and methods of treating human diseases, infections and other conditions using these antibodies.
    Type: Grant
    Filed: September 22, 2009
    Date of Patent: September 13, 2011
    Assignee: Medarex, Inc.
    Inventors: Alan J. Korman, Edward L. Halk, Nils Lonberg, Yashwant M. Deo, Tibor P. Keler
  • Transgenic Trasnchromosomal Rodents for Making Human Antibodies
    Publication number: 20110003319
    Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.
    Type: Application
    Filed: September 9, 2010
    Publication date: January 6, 2011
    Applicants: KYOWA HAKKO KIRIN CO., LTD., MEDAREX, INC.
    Inventors: KAZUMA TOMIZUKA, ISAO ISHIDA, NILS LONBERG, EDWARD L. HALK
  • HETEROLOGOUS ANTIBODIES WHICH BIND HUMAN CD4
    Publication number: 20100310453
    Abstract: The invention relates to transgenic non-human animals capable of producing high affinity human sequence antibodies. The invention is also directed to human sequence antibodies specific for human antigens, such as, human CD4. The invention also is directed to methods for producing human sequence antibodies.
    Type: Application
    Filed: April 29, 2010
    Publication date: December 9, 2010
    Inventors: Nils LONBERG, Robert M. KAY, Dianne M. FISHWILD
  • Transgenic Non-Human Animals For Producing Chimeric Antibodies
    Publication number: 20100287629
    Abstract: The invention relates to transgenic non-human animals capable of producing heterologous antibodies and methods for producing human sequence antibodies which bind to human antigens with substantial affinity.
    Type: Application
    Filed: September 26, 2008
    Publication date: November 11, 2010
    Inventors: Nils Lonberg, Robert M. Kay
  • Transgenic transchromosomal rodents for making human antibodies
    Patent number: 7816578
    Abstract: The present invention provides novel transgenic nonhuman mammals capable of producing human sequence antibodies, as well as methods of producing and using these antibodies.
    Type: Grant
    Filed: September 30, 2005
    Date of Patent: October 19, 2010
    Assignees: Kyowa Hakko Kirin Co., Ltd., Medarex, Inc.
    Inventors: Kazuma Tomizuka, Isao Ishida, Nils Lonberg, Edward L. Halk
  • Heterologous antibodies which bind human CD4
    Patent number: 7722873
    Abstract: The invention relates to transgenic non-human animals capable of producing high affinity human sequence antibodies. The invention is also directed to human sequence antibodies specific for human antigens, such as, human CD4. The invention also is directed to methods for producing human sequence antibodies.
    Type: Grant
    Filed: February 8, 2006
    Date of Patent: May 25, 2010
    Assignee: Genpharm International, Inc.
    Inventors: Nils Lonberg, Robert M. Kay, Dianne M. Fishwild